In what kind of patient scenario would you consider testing for inherited disorders of lipid metabolism in the evaluation of a patient with MASLD?

I usually am concerned about a monogenic cause of MASLD when the patient has steatosis without the traditional metabolic risk factors that we typically see. Additionally, if patients have other features such as severely low LDL in the setting of steatosis, rapidly progressive liver disease, early ag...

I personally start thinking about inherited or monogenic lipid disorders in a MASLD evaluation when the phenotype does not align with the usual metabolic risk pattern.

For me, the main triggers are:

1. Steatosis in the absence of classic metabolic risk factors such as obesity, diabetes, or insulin res...